IMAX CEO exercises options, sells 120K shares
IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting shares in a planned series of transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting shares in a planned series of transactions. He converted options into 120,132 common shares at $31.40 per share under a Rule 10b5-1 trading plan dated December 9, 2025.
On April 13–15, 2026, he then sold the same 120,132 common shares in open-market trades, including sales at $37.1526, $37.0678 and $37.0707 per share. Following these transactions, he directly owns 765,002 common shares, with remaining outstanding option, restricted share unit and common share balances of 1,417,273 options, 231,562 restricted share units and 765,002 common shares.
Insider Trade Summary 10b5-1
Exercise and Sale: 120,132 shares ($689K approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
GELFOND RICHARD L
Role
Chief Executive Officer
Sold
120,132 shs ($4.46M)
Approx. gross sale proceeds
$4.46M
Approx. exercise cost
$3.77M
Approx. pre-tax spread
$689K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | stock options (to buy) | 15,746 | $31.40 | $494K |
| Conversion | common shares | 15,746 | $31.40 | $494K |
| Sale | common shares | 15,746 | $37.0707 | $584K |
| Conversion | stock options (to buy) | 6,924 | $31.40 | $217K |
| Conversion | common shares | 6,924 | $31.40 | $217K |
| Sale | common shares | 6,924 | $37.0678 | $257K |
| Conversion | stock options (to buy) | 97,462 | $31.40 | $3.06M |
| Conversion | common shares | 97,462 | $31.40 | $3.06M |
| Sale | common shares | 97,462 | $37.1526 | $3.62M |
| holding | common shares (opening balance) | -- | -- | -- |
Holdings After Transaction:
stock options (to buy) — 1,417,273 contracts (Direct);
common shares — 765,002 shares (Direct);
common shares (opening balance) — 765,002 shares (Direct)
Footnotes (4)
- F1. Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025.
- F2. These options were issued in 2016 and are set to expire on June 7, 2026.
- F3. The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016.
- F4. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,417,273, 231,562 and 765,002, respectively.
Key Figures
Options exercised: 120,132 shares at $31.40
Shares sold: 120,132 common shares
Sale prices: $37.1526, $37.0678, $37.0707
+4 more
7 metrics
Options exercised
120,132 shares at $31.40
Stock option conversions into common shares
Shares sold
120,132 common shares
Open-market sales following option exercise
Sale prices
$37.1526, $37.0678, $37.0707
Per-share prices on April 13–15, 2026 sales
Shares held after
765,002 common shares
Direct ownership following transactions
Remaining options
1,417,273 options
Outstanding stock options after transactions
Remaining RSUs
231,562 RSUs
Restricted share units outstanding after transactions
Option expiry
June 7, 2026
Expiration date of exercised 2016 options
Key Terms
10b5-1 Plan, stock options, restricted share unit, open-market sale
4 terms
10b5-1 Plan regulatory
"conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
stock options financial
"Represents the conversion upon exercise of stock options into common shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IMAX (IMAX) CEO Richard Gelfond do in this Form 4 filing?
IMAX CEO Richard Gelfond exercised stock options and sold the resulting shares. He converted 120,132 options into common shares at $31.40, then sold those shares in open-market trades at prices around the high $37 range under a pre-set 10b5-1 plan.
At what price did the IMAX CEO exercise his stock options in this filing?
He exercised stock options at $31.40 per share. Those options, originally granted in 2016 and expiring June 7, 2026, were converted into 120,132 common shares before being sold in the market at prices slightly above $37 per share.
Were the IMAX CEO’s option exercises and sales under a Rule 10b5-1 plan?
Yes, the conversion of options into common shares was made under a Rule 10b5-1 plan dated December 9, 2025. Such pre-arranged trading plans allow executives to sell shares on a set schedule, helping separate trading decisions from short-term market movements.
What type of options did the IMAX CEO exercise and when do they expire?
He exercised stock options granted in 2016 with an exercise price of $31.40 per share. Footnotes explain these options were scheduled to expire on June 7, 2026 and had become exercisable in three installments during 2016 before this conversion and sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
